Literature DB >> 30976564

Contemporary surgical and technical aspects of transurethral resection of bladder tumor.

Idir Ouzaid1, Fréderic Panthier1, Jean-François Hermieu1, Evanguelos Xylinas1.   

Abstract

To date, transurethral resection of bladder tumor (TURBT) remains the gold standard of staging urothelial cancer of the bladder and treating non-muscle invasive bladder cancer (NMIBC). The primary goal of the procedure includes a proper diagnosis, correct staging, and removal all lesions. Herein, we discuss major contemporary surgical and technical aspects of including en bloc resection, bipolar and laser resection as well as quality control of TURBT.

Entities:  

Keywords:  Non-muscle invasive bladder cancer (NMIBC); endoscopy; surgery; transurethral resection of bladder tumor (TURBT); treatment

Year:  2019        PMID: 30976564      PMCID: PMC6414345          DOI: 10.21037/tau.2019.01.04

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


Introduction

Transurethral resection of bladder tumor (TURBT) remains the gold standard of staging urothelial cancer of the bladder and treating non-muscle invasive bladder cancer (NMIBC) (1). TURBT aims proper diagnosis, correct staging, and remove of all lesions. Indeed, residual tumor after initial TURBT is associated with a higher risk of disease recurrence (2). Therefore, complete and optimal TURBT is crucial to achieve good oncological outcomes. Given this cornerstone role, achieving a high-quality resection should be the first step of the primary management of NMIBC. This resection requires best of care in terms of diagnosis, visualization, disease burden assessment, resection and optimal specimen analysis. Herein, we discuss the major contemporary surgical and technical aspects including en bloc resection, bipolar and laser resection as well as best standards for TURBT. New visualization and detection techniques and re-TURBT are not discussed in the current article.

Surgical and technical aspect of TURBT

Cystoscopy and mapping

The first step of the TURBT includes a thorough cystoscopy. During this step, fresh urine can be collected for urine cytology if not performed earlier. The cystoscopy assesses the number, the location, and the aspects of all suspicious lesions. Specifically, the distance to the ureteral orifices, the trigonal lesions, bladder neck, and prostatic urethra invasion. The EAU guidelines recommend a standardized mapping (1). The mapping may be useful when a distinct pathology reports is warranted in some clinical scenarios.

Resection type: conventional vs. en bloc resection

TURBT using a wire loop is considered the gold standard for staging and treating NMIBC. However, the piecemeal resection, the potential scattering of tumor cells, the absence of detrusor muscle (DM) in the resected specimen are thought to be drawbacks of the conventional resection. Thus, in order to improve the quality of the resection and, ultimately decreasing the recurrence rate, the en bloc resection was introduced (3). Different options, including loop modifications, laser techniques and water-jet based enucleation, have been reported (3-6). The “en bloc” technique include the incision of the surrounding mucosa with a safety margin to detach the tumor in one piece. Care should be taken to get deep enough in the bladder wall to remove DM (7). Studies could demonstrate DM in all cases and the resection of tumor up to 7.5 cm (4,8). However, this approach failed to demonstrate any improvements of oncological outcomes.

Energy

Modifications, such as bipolar TURBT have several advantages such as reduction of the obturator nerve injury. In fact, stimulation of the nerve may lead to the patient motion that can cause bladder perforation (7). In addition, bipolar vaporization allows, enucleation and debulking techniques and subsequent resection of the tumor base (7). However, bipolar TRUBT doesn’t preclude resection requirements including complete tumor removal and muscle sampling. A recent systematic review and meta-analysis that compared bipolar and monopolar TURBT did not report any statistically significant differences between bipolar TURBT and monopolar TURBT for rates of obturator nerve reflex, bladder perforation, and transfusion. Cautery artifacts were similar in both procedures. There was no significant difference in disease recurrence rates when comparing the two types of procedures (9).

Bladder neck and prostate biopsy

The biopsy of the bladder neck and the prostatic urethra with there is an evidence of disease is not questioned. However, in some cases, the involvement is not visible. The risk of involvement is higher in case of carcinoma in situ (CIS), high-grade tumor, and positive cytology without evidence of the disease in the bladder (10). When indicated, the biopsy from abnormal areas in the prostatic urethra and from the precollicular area (between the 5 and 7 o’clock position) are performed using a resection loop or cold-cup biopsy when stromal invasion is not suspected (1).

Quality control

The aims of TURBT include the resection of all macroscopic lesions, establish pathological stage and grade and identify significant prognostic factors (2). These being of the utmost importance for patient management, quality control of the procedure is mandatory. Pathologists and urologists have both a major play role in achieving a gold standard procedure. According, to the International Society of Urological pathology (ISUP) recommendations, pathology reports should be standardized and should at least mention tumor stage and grade, the presence of DM in the resected specimens, the present of any histological variants, and concomitant CIS (11). A permanent dialogue between urologists and pathologists should be established to review cases and confront pathological findings with clinical findings. From a surgical perspective, a good-quality TURBT is not always achieved because of poor cystoscopic view, tumor size, multifocality of the disease, difficult location, an inexperienced surgeon or complications such as bleeding or bladder perforation. Inadequate tumor clearance results in early recurrence and inaccurate staging of the cancer. After reviewing published controlled studies, the recurrence rate at the first follow-up cystoscopy (RRFFC) was introduced by the European Organization for Research and Treatment of Cancer (EORTC) (12). It was concluded that this discrepancy was a result of variability in the quality of the resections. A low RRFFC was reported to be associated with the presence of DM on the specimen which is significantly more achieved when the procedure was performed by a senior surgeon (13). DM in the specimen is easy to identify allowing an immediate quality control of TURBT. Another way of improving the quality of TURBT is the implementation of a check-list in order to standardize the surgical procedure and therefore enhance its performance and improve surgical and oncological outcomes. As such, an eight-item check-list was reported to improve disease-free survival after TURBT but failed to improve the rate of DM in the resected specimens (14). Finally, the best TURBT is achieved when the procedure is performed in standardized fashion (). This standardization should be part of the training process of junior urologists.
Table 1

Checklist for a good TURBT

Preoperative
   Sterile urinalysis
   Urine cytology
   Imaging reviewing
   Upper tract clearance if high-grade
   Procedure modality
   White light ± (blue light or narrow band imaging or other)
Operative
   Urethral assessment
   Bladder assessment
   Macroscopic appearance
   Number of lesions
   Mapping of lesions
   Involvement of the trigone and/or bladder neck
   Proximity to/involvement the ureteral orifices
   Macroscopic clearance after resection
   Surgical complications
   Perforation
   The need of specific specimen to be sent separately
Postoperative
   Pathology report review
   Histology type
   Stage, grade, concomitant CIS
   ISUP/WHO classification
   Presence of DM (detrusor muscle)
   EORTC risk assessment
   The need of second look/complimentary TURBT

CIS, carcinoma in situ; DM, detrusor muscle; TURBT, transurethral resection of bladder tumor; ISUP, International Society Of Urological Pathology; WHO, World Health Organization.

CIS, carcinoma in situ; DM, detrusor muscle; TURBT, transurethral resection of bladder tumor; ISUP, International Society Of Urological Pathology; WHO, World Health Organization.

Conclusions

TURBT is a cornerstone of the primary management of bladder tumors. Achieving a high-quality resection allows a correct treatment, staging and classification of the tumor. Because of the jeopardized prognosis of a bad TURBT, the procedure should be performed by experienced surgeons or strictly supervised when performed by trainees. Ideally, procedure should be standardized according to best practice recommendations.
  4 in total

1.  Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer.

Authors:  Lauren Lett; Michael George; Rachael Slater; Ben De Lacy Costello; Norman Ratcliffe; Marta García-Fiñana; Henry Lazarowicz; Chris Probert
Journal:  Br J Cancer       Date:  2022-03-29       Impact factor: 9.075

2.  Bladder cancer histological variants: which parameters could predict the concordance between transurethral resection of bladder tumor and radical cystectomy specimens?

Authors:  Guglielmo Mantica; Stefano Tappero; Stefano Parodi; Nataniele Piol; Bruno Spina; Rafaela Malinaric; Federica Balzarini; Marco Borghesi; André Van Der Merwe; Nazareno Suardi; Carlo Terrone
Journal:  Cent European J Urol       Date:  2021-09-09

Review 3.  Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.

Authors:  Kuan-Wei Shih; Wei-Chieh Chen; Ching-Hsin Chang; Ting-En Tai; Jeng-Cheng Wu; Andy C Huang; Ming-Che Liu
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

4.  Lentinan Inhibits Tumor Progression by Immunomodulation in a Mouse Model of Bladder Cancer.

Authors:  Ming Sun; Renge Bu; Bin Zhang; Yaming Cao; Chengyang Liu; Wenyan Zhao
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.